## A genetic association study of two genes linked to neurodegeneration in a Sardinian multiple sclerosis population: the *TARDBP* Ala382Thr mutation and *C9orf72* expansion

L. Lorefice<sup>1</sup>, M.R. Murru<sup>2</sup>, G. Fenu<sup>1</sup>, D. Corongiu<sup>2</sup>, J. Frau<sup>1</sup>, S. Cuccu<sup>2</sup>, G. Coghe<sup>1</sup>, S. Tranquilli<sup>3</sup>, M.G. Marrou<sup>4</sup>, E. Cocco<sup>1</sup>

<sup>1</sup>Multiple Sclerosis Center, Department of Public Health and Clinical and Molecular Medicine, University of Cagliari <sup>2</sup>Multiple Sclerosis Center, ASL8-Department of Medical Sciences, University of Cagliari <sup>3</sup>Institute of Neurology, ASL8-Department of Medical Sciences, University of Cagliari <sup>4</sup>Multiple Sclerosis Center, Department of Medical Sciences, University of Cagliari

**Background**. Multiple sclerosis (MS) is a chronic disease of the central nervous system characterized by inflammation and accompanied and followed by neurodegeneration. Missense mutations of the TAR DNA Binding Protein gene (TARDBP) located in the chromosome 1p36.22 region, and the hexanucleotide repeat expansions in chromosome 9 open reading frame 72 (C9orf72) are pathogenic in other neurodegenerative diseases such as amyotrophic lateral sclerosis and frontotemporal lobar degeneration. <sup>2,3</sup>

**Aim.** Assuming that TARDBP Ala382Thr mutation and C9orf72 expansion may underlie MS, we evaluated their frequency in a large cohort of MS patients and controls from Sardinia, an island characterized by a very high frequency of MS and an unusual genetic background.

**Methods.** Genomic DNA was extracted from peripheral blood and analyzed for the presence of a TARDBP Ala382Thr mutation and C9orf72 expansion. Difference in the frequency of these mutations between MS patients and controls was calculated using the  $\chi^2$  test with a standard 2×2 table.

Table 1 Demographic feature of the overall subjects TDP-43 mutation analyzed in this study

TDP-43 sample	HCs	MS
3308	1475	1833
MEAN AGE, YEARS	54,1±15,2	41,1±11,8
TARDBPAla382Thr mutation	20 (1,3%)	27 (1,4%)

The TARDBP p.Ala382Thr mutation in the heterozygous state was detected in 27 of 1833 (1.4%) MS patients and 20 of 1475 (1.3%) HCs. No difference in its frequency between MS patients and HCs was observed (p=0.8)

Table 2. Demographic features of the overall subjects C9ORF72 expansion analyzed in this study.

TOTAL SAMPLE ANCHOR PCR	MS ALL	HC ALL	
1347	1014	333	
MEAN AGE, YEARS	49,7±32,0	63,1±36,5	
SEX, FEMALE	67,30%	53,40%	

MS SPORADIC 655

MS FAMILIAL 359
MS Parents 45
MS Offspring 312
MS sisters 2

Table 3. C9ORF72 expansion analysis: ANCHOR PCR size classification in MS groups and HCs

	ANCHOR PCR SIZE			
	≤ 20	21-25	26-30	> 30
MS SPORADIC				
(655)	651	0	2	2
MS FAMILIAL (359)				
Parents (49)	46	1	0	2
Offspring (310)	305	1	2	2
HEALTY (333)	327	1	3	2

Pathogenic repeat expansion (>30 repeats) was found in two sporadic MS patients, four familial MS patients, and two HCs (total MS patients vs HCs P=0.9; sporadic vs familial MS; P=0.1)

Individuals carrying the mutations did not present with other neurodegenerative conditions and any differences were reported between groups.

**Conclusions.** *TARDBP* Ala382Thr variant and *C9orf72* expansion do not play a major role in MS pathogenesis in the Sardinian population. Further analyses are needed to better define the possible role of these genetic variants in neurodegenerative process in MS.

References: 1. Charil A, at Al. J Neurol Sci. 2007 Aug 15;259(1-2):7-15.

2. Lattante S, et Al. Hum Mutat. 2013 Jun;34(6):812-26.

3 . Renton AE, et Al. Neuron. 2011 Oct 20;72(2):257-68.

Disclosure: No conflict of interest exists regarding the present study